US Private DEFUNCT 2018

Theranos, Inc.

Blood testing startup whose founder fabricated testing capabilities, commercial partnership revenues, and military contract claims.

CORPORATE IDENTIFIERS & DOSSIER
  • Entity Name: Theranos, Inc.
  • Country of Domicile: US
  • Listing & Ticker: Private.
  • CIK / LEI Identifier: Unregistered.
  • Industry Classification: General Commercial.
  • Cumulative Overstatement: $700.0M across 1 enforcement episode(s).
  • Assessed Penalties: $500K.

PRIMARY ENFORCEMENT CASES INVOLVING THERANOS, INC.

1 CASE DOSSIERS
Case Title Status Primary Scheme Overstatement Total Penalties Action Date
Theranos: Fabricated Revenue Projections and Fake Blood Analyzer Demos Adjudicated misleading non gaap and kpis $700.0M $500K September 20, 2020

FORENSIC PROFILE: THERANOS: FABRICATED REVENUE PROJECTIONS AND FAKE BLOOD ANALYZER DEMOS

FULL CASE DOSSIER →

Elizabeth Holmes and Sunny Balwani deceived investors with fake DOD contract claims, false revenues, and proprietary analyzer demos run on commercial machines.

The company manipulated its accounting records by executing schemes under misleading-non-gaap-and-kpis. Financial reports filed with market regulators contained material misstatements that distorted true financial condition.

Fraud Window: January 1, 2018 to December 31, 2020 • Primary Regulator: U.S. Securities and Exchange Commission • Auditor: PricewaterhouseCoopers LLP

Documented Accounting Irregularities & Regulatory Findings

  • MISLEADING NON GAAP AND KPIS: Elizabeth Holmes and Sunny Balwani deceived investors with fake DOD contract claims, false revenues, and proprietary analyzer demos run on commercial machines.

Primary Public Dockets & Actions

  • [ENF-2018-theranos] Enforcement Action: Theranos: Fabricated Revenue Projections and Fake Blood Analyzer Demos (September 20, 2020): Elizabeth Holmes and Sunny Balwani deceived investors with fake DOD contract claims, false revenues, and proprietary analyzer demos run on commercial machines. Official Record ↗